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INTRODUCTION
1INTRODUCTION
GLOBAL TRENDS IN STROKE
Stroke is a Non-communicable disease of increasing socioeconomic
importance in ageing populations. According to WHO, stroke was the second
commonest cause of worldwide mortality in 1990 and, the third commonest
cause of mortality in more developed countries. it was responsible for about 4·4
million deaths worldwide. In the recent estimates made in 1999, the number of
deaths due to stroke reached 5·54 million worldwide, with two-thirds of these
deaths occurring in less developed countries. Stroke is also a major cause of
long-term disability and, has potentially enormous emotional and
socioeconomic consequences for patients, their families, and health services.
The case-fatality rate due to stroke is reported to vary from 11.7% to 32.4%.
In 2005, estimates indicated that 58 million people died, and in them
chronic diseases accounted for 35 million deaths (60%).
Cardiovascular diseases, predominantly heart disease and stroke, were
the cause of death in 17·5 million individuals. After heart disease, Stroke is the
second leading single cause of death, with 5·8 million fatal cases per year, 40%
of which are in people younger than 70 years. About 15 million new acute
stroke events arise every year, and about 55 million people have had a stroke at
some time in the past, either with or without residual disability; two-thirds of
these individuals live in low income and middle-income countries.
2Demographic changes, urbanization, and increased exposure to major
stroke risk factors will fuel the stroke burden in the future. By 2025, four out of
five stroke events will occur in people living in these regions. The prevalence
of stroke in India varies in different regions of the country and, ranges from 40
to 270 per 100 000 population.    Approximately 12% of all strokes occur in the
population <40 years of age. Major risk factors identified in India are
hypertension (blood pressure >95 mm Hg diastolic), hyperglycemia, tobacco
use, and low hemoglobin levels (<10 gm %). Stroke accounts for 2 percent of
hospital registrations, 1.5 percent of medical registrations and 9 to 30 percent
of neurological admissions in major hospitals.
The National Commission on Macroeconomics and Health has projected
that cases of stroke would increase from 1,081,480 in 2000 to 1,667,372 in
2015.
3BURDEN OF STROKE IN INDIA2
Year/Age
(Years)
Estimated prevalence
of stroke per 1000
Estimated
population
Estimated cases
2000
   20 – 39
   40 – 59
   60 – 79
   Others
   Total
0.3022
2.7188
8.4733
306,904,000
168,223,000
62,711,000
464,304,000
1,002,142,000
92,746
457,365
531,369
----
1,081,480
2005
   20 – 39
   40 – 59
   60 – 79
   Others
   Total
0.3022
2.7188
8.4733
346,437,000
196,422,000
71,883,000
468,027,00
1,082,769,000
104,693
543,032
609,086
----
1,247,812
2010
   20 – 39
   40 – 59
   60 – 79
   Others
   Total
0.3022
2.7188
8.4733
392,531,000
227,674,000
84,168,000
463,688,000
1,168,061,000
118,623
619,000
713,181
----
1,450,804
2015
   20 – 39
   40 – 59
   60 – 79
   Others
   Total
0.3022
2.7188
8.4733
428,582,000
258,731,000
98.476,000
466,053,000
1,251,842,000
129,517
703,438
834,417
----
1,667,372
4STUDIES ON STROKE  DONE  IN  INDIA
Place Age Group No.of
Patients
Aim of the study
Nayak et al Trivandrum 15 – 45 Years 177 Clinical features
and risk factors
Lipska et al Trivandrum 15 – 45 years 214 Risk factors
Razdan et al Rural
Kashmir
>15 years, sub group
15 – 39, 40 – 49 years
91 Prevalence
study
Abraham et al Vellore All age groups 147 Prevalence
study
Das et al Kolkata All age groups,
subgroup <40 years
and >40 years
247 Prevalence and
incidence study
Dalal et al Mumbai >25 years, subgroups
25 – 34 and 35 – 44
years
456 Incidence study
5STUDIES ON  STROKE  DONE  OUTSIDE  INDIA
Place/Country Age group
(years)
No. of patients
Adams et al Lowa, USA 15 – 45 329
Kittner et al Baltimore, USA 15 – 44 428
You et al Melbourne, Australia 15 – 55 201
Marini et al La Aquila <45 89
Jacobs et al Manhattan, NY, USA 20 – 44 74
Lee et al Taiwan 18 – 45 264
Leys et al France 15 – 45 287
Kristensen et al Sweden 18 – 44 107
Nedeltchev et al Switzerland 16 – 45 203
Putaala et al Helsinki 15 – 49 1008
Verona et al Spain 15 – 45 272
AIMS  AND OBJECTIVES
6AIMS AND OBJECTIVES
1.  To determine the prevalence of elevated homocysteine level in 50 patients
     with stroke in young .
2.  To study about the role of homocysteine levels in predicting morbidity and
     mortality.
3.  To study about prognostic implication of elevated homocysteine level.
REVIEW  OF  LITERATURE
7REVIEW OF LITERATURE
STROKE IN YOUNG
Stroke is a major public health problem.  Stroke is also the most
common neurological condition causing long-term disability and has enormous
emotional and socioeconomic consequences in patients, their families and
health services. The latest available estimates from Indian Council of Medical
Research (ICMR) indicate that in 2004 there were 930,985 cases of stroke in
India with 639,455 deaths and 6.4 million disability adjusted life years (DALY)
lost.
In India the incidence of stroke is likely to rise in the coming years due
to:
a. Increase in population
b. Increase in life expectancy
c. Rapid urbanization from migration of villagers to the cities
d. Changing lifestyles involving sedentary habits, smoking, excess
alcohol use, etc.
e. Rising stress level in life
According to the estimates by the National Commission on
Macroeconomics and Health, India, there will be 1.67 million stroke cases in
India in 2015.
AGE AND STROKE INCIDENCE
Age has the strongest association with the incidence of stroke. For
example, an 80 year old has about 30 times the risk of ischemic stroke than a
850 year old3.  The age-specific incidence of stroke increases progressively with
increasing age. In a systematic review of 15 population-based stroke incidence
studies4, the rate of total stroke for those aged less than 45 years ranged from
0.1-0.3 per 1000 person years, while for those aged 75-84 years, the range was
12-20 per 1000 person years in most studies. However, the impact of stroke on
the individual family and society is strongest when it affects a young
individual. Therefore, stroke in young attracts a large share of attention,
perhaps disproportionately large. Therefore, in India as well as in other
countries, there has been a large body of literature addressing the issues related
to stroke in young. This review is an attempt to summarize some of this
literature with special reference to the Indian context.
Clinical management as well as epidemiologic perspective raises several
issues in relation to stroke in young.  Important issues amongst these include
the following:
a. Which age group should be included under the definition of ‘young’?
b. Are young Indians more susceptible to stroke than their counterparts in
other countries, particularly western countries?
c. Are there age or sex-specific differences in the etiology of stroke
between 'young' and 'older' adults? If so, are the differences quantitative,
qualitative or both?
d. Which additional investigations are indicated for stroke in Indian
young?
e. Are there specific genetic factors predisposing young Indians to stroke?
9The age group included in studies on stroke varies widely in the reports
published in literature. The lower limit of the age varies from 0 to 25 years in
various reports with majority keeping it at 15 years. The upper age limit also
varies from 40 to 55 years, majority being around 45 years. The wide variation
compromises comparisons across the studies and confounds communication
among experts. The rationale for the choice of age group is not given in the
reports. The following points need consideration while defining the age
category for young.
a. The unique set of causes affecting certain age groups has to be
considered. This will allow identification of priority causes for the
defined age group. In this context, rheumatic heart disease, peripartum
stroke, arterial dissection and vascular malformations need special
attention. All of these are exceedingly rare before the age of 15 years
and after 50 years. A focus on the age group 15-50 years will allow
estimation of the contribution of these causes to stroke in young.
b. Pregnancy-related causes of ischemic, hemorrhagic and venous strokes
are unique to females in the reproductive age group. A large body of
socioeconomic data in this age group has accumulated through a series
of National Family Health Surveys (NFHS), the third one conducted in
2005-2006. This survey interviewed women aged 15-49 years and men
aged 15-54 years. Thus, restricting the age group for 'stroke in young'
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between 15 and 50 years would allow correlational studies with NFHS
data.
c. Preventive strategies for the two common causes (rheumatic heart
disease and pregnancy) of stroke in young and some others like
infections related stroke need to be unique. Data and research in this age
group would permit development of evidence-based strategies for
prevention.
d. The latest estimates of 2006 indicate that the age group 15-49 years
constitutes 52% of the population in India. Therefore, in our opinion,
future studies may consider keeping 15-49 years (<50 years) as the age
group for studies on stroke in young.
High Susceptibility of 'Young' Indians to Stroke
Several hospital-based studies on stroke in young adults from India had
hypothesized that young Indians are more susceptible to stroke than their
counterparts from industrialized countries.  Older studies says: 'Indians as a
whole are probably more susceptible to stroke than people in industrialized
countries and that the magnitude of increased susceptibility is probably similar
for the young and older adults … to answer this question, a well designed study
is required in India which can be compared to a similar contemporary study in
the west'.  There are two recent studies10 from Kolkata and Mumbai that allow
us to compare the age-specific incidence between India and other countries. It
is clear that young adults in India are not more susceptible to stroke than their
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counterparts in the west, though Das et al9 have noted that for all age groups
together standardized rate of stroke incidence (123.5/100,000/year) is higher
than that observed in USA (107/100,000/year), European countries (61-
111/100,000/year), and Australia (99/100,000/year). These data, together with
the studies on Indian immigrants to UK and the USA, suggest that Indians in
general may probably be more susceptible to stroke but there is no age-specific
higher susceptibility for the young. Previous hospital-based studies from India
showing a high proportion of young strokes, ranging between 15 and 30%,
were over estimates probably because of a preferential admission policy.
One area that remains to be well documented is the incidence of
peripartum stroke. There is a strong impression among clinicians that the
incidence is several times higher than that in other countries, particularly in
industrialized countries.
Stroke Subtypes, Risk Factors and Etiology
The 'mix' of causes, the proportion with 'no cause' and the outcome of
stroke in young varies from one series to the other. While some of the
variations may be real, the majority is probably explained by the referral bias,
differences in admission policy, in the pattern/availability of emergency
services, investigation intensity and diagnostic criteria. All these may change
with time as more causes are discovered and new diagnostic technologies
become available. No two series are, therefore, strictly comparable. The
following paragraphs may be read with this caveat in mind.
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The  prevalence of various risk factors in stroke in young has been
analyzed in two studies from India5.  In a case control study of young stroke
patients (age group 15-45 years) with age and sex-matched hospital and
community controls6, prevalence of various risk factors was studied. Two
hundred fourteen South Indian patients with first acute ischemic stroke and 99
hospital and 96 community controls were included. There was higher
prevalence of smoking (odds ratio [OR] 7.77), systolic blood pressure (OR
1.88) and fasting blood glucose (OR 4.55) in patients. High density lipoprotein
(HDL) was low and total cholesterol/HDL ratio was high in cases when
compared with both hospital and community controls. A unit increase in the
ratio of total cholesterol to HDL was associated with doubling of stroke risk.
More than three components of metabolic syndrome were present in 12.6%
cases when compared to 6% of community controls. Presence of ?3
components of metabolic syndrome was also strongly associated with stroke(or
4.76). .
In another study in 1997, 177 patients with first ever ischemic stroke
(age group 15-45 years) were included retrospectively based on hospital data,
with 76% male and 24% female patients. Hypertension was present in 18% of
the patients, whereas diabetes mellitus was present in 7% only. Sixty nine
percent of male patients were smokers.  Dyslipidemia in the form of elevated
cholesterol was present in 17% and increase in triglycerides was observed in
42%patients.
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Sridharan et al23 analyzed the risk factors in ischemic stroke including
the patients of all age groups. Hypertension, ECG abnormality, heart disease of
any type, diabetes, smoking and alcohol were associated with stroke. Low HDL
and low density lipoprotein (LDL) to HDL ratio was observed among stroke
patients. South Asians living in UK are known to have an atherogenic lipid
profile, which includes raised triglycerides, low HDL cholesterol and raised
lipoprotein (a) level24.
 In a study of stroke in the young from Southeast Asia16, the most
common risk factors observed were hyperlipidemia (53.1%), smoking (49.8%),
hypertension (45.8%) and a family history of stroke (29.3%). The presence of
hyperlipidemia and hypertension was more commonly seen in patients with
small vessel occlusion, large artery atherosclerosis and stroke due to unknown
etiology, whereas hyperlipidemia was less commonly associated with
caradioembolic stroke.
Analysis of prevalence of risk factors in studies of stroke in young from
the west reveals prevalence of hypertension from 20 to 60%18,19.   In Baltimore
Washington Cooperative Young Stroke Study12 examining 296 incident stroke
cases in Black and White adults, hypertension was present in 61% of Black
patients. Smoking was observed in 42.6% of White and 56.7% of Black men
and 37.0% of White and 47.5% of Black women.
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In Helsinki Young Stroke Registry20 which included 1008 first ever
patients of ischemic stroke in the age group of 15-49 years, hypertension,
smoking and dyslipidemia with high total cholesterol emerged as important risk
factors. The prevalence of hypertension increased with increasing age and was
seen in 28.3% of patients in 15-44 year age group, whereas it was prevalent in
51.7% of patients in 45-49 year age group. Similarly, 38.4% of patients in 15-
44 year age group and 54.5% in 45-49 year age group had increased level of
cholesterol. Low HDL was present in 15.3 and 23.9% of the patients,
respectively. Increased LDL was also present in 38.4% patients in 15-44 year
age group and in 54.5% patients in 45-49 year age group. Smoking as a risk
factor was observed in around 47% patients in both the age groups. It appears
that the risk factor profile becomes similar to older population with increasing
age, the change becoming more apparent at around 44 years of age.
In a study of 203 patients of stroke in age group of 15-45 years from
Switzerland19, hypercholesterolemia (39%) and smoking (46%) were important
risk factors. However, hypertension was present in 19% patients only.
Increased C reactive protein level was observed in 36% patients.
It appears that the risk factors for stroke in Indian population are not
different from the western or Southeast Asian population. The traditional risk
factors like hypertension, smoking and diabetes are associated with stroke in
both young and elderly. The role of dyslipoproteinemia in the pathogenesis of
cerebrovascular disease is less certain than that of coronary artery disease;
15
however, increased total cholesterol and increased triglyceride levels have been
observed in patients from India and Southeast Asia. Increased level of total
cholesterol has been associated with ischemic stroke in young in most of the
populations and it does not significantly differ from the Indian subcontinent.
In a study on stroke in young from Sri Chitra Tirunal Institute of
Medical Sciences and Technology (SCIMST), Trivandrum6,  patients of
ischemic stroke were classified based on Trial of ORG 10172 in Acute Stroke
Treatment (TOAST) criteria; 25.2% patients had cardioembolic stroke, 12.6%
had large artery atherosclerosis and 7.5% had lacunar infarcts. Strokes due to
other determined etiology were 11.2% (7.0% arterial dissection, and one
patient each with lupus erythematosus, primary antiphospholipid antibody
syndrome and protein S deficiency). Four patients had stroke due to other
causes (one case each of Moya moya disease, Takayasu's arteritis,
fibromuscular dysplasia and nephritic syndrome).
Data from several studies indicate that 21-48% of strokes in the young
are caused by atherosclerotic large artery occlusive disease, 10-33% are due to
nonatherosclerotic large artery occlusive disease (dissections have comprised
10-20% in some studies), 13-35% are caused by cardioembolism, 3-18% by
penetrating artery disease, 8-15% by prothrombotic states and 4-15% by
miscellaneous causes. Cryptogenic stroke comprises 7-40% of the cases. In a
study by Lee et al16 vascular risk factors like hypertension, diabetes,
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hyperlipidemia were seen more commonly in patients with large artery
atherosclerotic disease or small vessel occlusive disease.
Cervical artery dissection was one of the relatively common causes of
stroke in young. Various studies report that around 6-15% of the patients had
carotid artery dissection. Carotid and vertebral artery dissection were seen with
a variable frequency. In one study, 24 patients had arterial dissection of 17016
patients who underwent angiographic studies, with carotid dissection in 13 and
vertebral dissection in 11. The commonest site for carotid dissection was just
above the carotid bifurcation. Putaala et al20 in a study of stroke in young from
Helsinki, reported that 59% of patients with stroke of other determined etiology
had cervical or intracranial artery dissection. Out of 155 patients with
dissection, 80 had vertebral artery dissection and 67 had internal carotid artery
dissection. Other causes of stroke like antiphospholipid antibody syndrome,
factor V Leiden mutation, proteins C and S deficiency, antinuclear antibody
positivity, systemic lupus erythematosus, fibromuscular dysplasia, migraine-
related stroke and other vasculitis were observed in 1-2% of patients.
The common causes of cardioembolic stroke include rheumatic heart
disease, paradoxical embolism due to patent foramen ovale (15-37% of
cardioembolic strokes), atrial fibrillation (10-14% of cardioembolic strokes),
mitral valve prolapse (1-38%), mechanical prosthetic valves, dilated
cardiomyopathy, atrial myxoma, congestive heart failure and sick sinus
syndrome.
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Genetics
Several candidate genes have been found to be associated with stroke.
Angiotensin converting enzyme (ACE) insertion/deletion polymorphisms,
methylenetetrahydrofolate reductase (MTHFR) mutations, apolipoprotein E
polymorphisms and phosphodiesterase 4D (PDE4D) gene variants have been
studied in Indian population.
 In a case control study, apolipoprotein E genotypes were studied in
patients of stroke34.  A high frequency of apo ? 4 allele (30% in cases and 11%
in controls) was observed (OR 4.2). The authors concluded that presence of apo
? 4 allele along with elevated triglycerides, hypertension and age could predict
the development of stroke. In another case control study from Hyderabad,35
angiotensin converting enzyme deletions/insertions were studied. The ORs for
ID genotype, DD genotype and D allele as an independent risk factor for
ischemic stroke were 2.89, 3.68 and 2.13, respectively. Presence of D allele
was also associated with intracranial atherosclerosis.
MTHFR C677T mutations were studied in patients with both arterial and
venous stroke with elevated homocysteine levels.36 The prevalence of the
mutated homozygous and heterozygous C677T MTHFR genotype in the
patients with arterial stroke was 1.4 and 31.88%, respectively. Their frequency
was 16.6 and 33.3% in venous stroke. The genotyping results from controls
showed that there was only one heterozygote out of the 49 studied. The
18
mutated allele was present in 25.4% of patients in age group of 15-50 years.
OR for the probability of the C677T MTHFR gene mutation in the patients
versus control group was 22.29 indicating that C677T MTHFR mutation is
strongly associated with arterial stroke especially in young adults.
PDE4D gene seems to contribute to the risk of stroke in carriers
independent of other genetically based risk factors.37 The association of
PDE4D with stroke was investigated in a South Indian population.38 PDE4D
gene polymorphisms were studied in 250 cases and controls. Single nucleotide
polymorphism (SNP) 83 showed significant association with stroke in the
population under study, whereas SNPs 87 and 32 were monomorphic. SNP 83
was found to be significantly associated with two stroke subtypes, intracranial
large artery atherosclerosis (the most frequent subtype in the population) and
small artery occlusion. The role of G20210A in ischemic stroke patients was
studied in a case control study from South India.39 None of the study subjects
were either heterozygous or homozygous for this gene mutation as indicated by
polymerase chain reaction (PCR) analysis. ACE gene polymorphism is
presently being studied in patients of both ischemic and hemorrhagic stroke
with age-matched controls. The above studies point toward an association
between ACE gene mutations, MHTFR mutations and PDE4D polymorphisms
with Homocysteine.
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Cerebrovascular diseases characteristic of each age period
1. Prenatal circulatory diseases leading to:
a. Porencephaly
b. Hydranencephaly
c. Hypoxic-ischemic damage
d. Unilateral cerebral infarction
2. Perinatal and postnatal circulatory disorders resulting in:
a. Cardiorespiratory failure and generalized ischemia—e´tat
    marbre
b. Periventricular infarcts
c. Matrix hemorrhages and ischemic foci in premature infants
d. Hemorrhagic disease of the newborn
3. Infancy and childhood: vascular diseases associated with:
a. Ischemic infarction
b. Congenital heart disease and paradoxical embolism
c. Moyamoya
d. Bacterial endocarditis, rheumatic fever, lupus erythematosus
e. Sickle cell anemia
f. Mitochondrial disorders (MELAS)
g. Homocystinuria and Fabry’s angiokeratosis
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4. Adolescence and early adult life: vascular occlusion or hemorrhage with:
a. Pregnancy and puerperium
b. Estrogen-related stroke
c. Migraine
d. Vascular malformations
e. Premature atherosclerosis
f. Arteritis
g. Valvular heart disease
h. Sickle cell anemia
i. Antiphospholipid arteriopathy, plasma C-protein deficiency and other
   coagulopathies.
j. Moyamoya, Takayasu disease
k. Arterial dissections
l. Amyloid angiopathy
5. Middle age:
a. Atherosclerotic thrombosis and embolism
b. Cardiogenic embolism
c. Primary (hypertensive) cerebral hemorrhage
d. Ruptured saccular aneurysm
e. Dissecting aneurysm
f. Fibromuscular dysplasia
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6. Late adult life:
a. Atherosclerotic thrombotic occlusive disease
b. Embolic occlusive disease
c. Lacunar state
d. Brain hemorrhage (multiple causes)
e. Multi-infarct dementia
f. Binswanger disease
22
PREVALENCE OF VARIOUS AETIOLOGIES IN PATIENTS WITH STROKE IN YOUNG
LAA – Large artery atherosclerosis; SVO – Small vessel occlusive disease; CE – Cardioembolism;
ODE – Other determined etiology, UDE – Undetermined etiology, NM – Not mentioned
Age
Group
Patient
No.
LAA SVO CE ODE/Venous
thrombosis
UDE
Bansal et al., (India) 1973 15 – 45 177 24 NM 17 0.6 36
Chopra et al., (India) 1979 <40 182 60 NM 15 22.5 NM
Dalal et al., (India) 1979 <45 81 51 NM 42 7 NM
Radhakrishnan et al., (Libya) 1986 15 – 40 63 54 NM 21 3 22
Bougousslavsky et al., (Switzerland) 1987 16 – 29 41 5 NM 29 5 10
Chanellor et al., (New Zealand) 1989 <40 66 NM NM 7.5 3 32
Lanzino et al., (Italy) 1991 16 – 45 155 31 NM 3 3 40
Lisovosky et al., (France) 1991 5 – 40 148 22 NM 13 NM 20
Leno et al., (Spain) 1993 <50 81 30 NM 17 NM NM
Adams et al., (Lowa, USA) 1995 15 – 44 329 21.6 8.2 19.5 24.5 25.7
Nayak et al., (India) 1997 15 – 45 177 24 NM 17 22 36
You et al., (Australia) 1997 15 – 55 201 52 22 10 NM 15
Kristensen et al., (Sweden) 1997 18 – 44 107 12 4.6 33.1 30.7 19.6
Kittner et al., (Baltimore, USA) 1998 15 – 44 428 2 10 15 35 38
Leys et al., (France) 2002 15 – 45 287 8.4 1.7 5.2 22.3 62.4
Jacobs et al., (Manhattan, USA) 2002 20 – 44 74 15 18 6 6 55
Lee et al., (Taiwan) 2002 15 – 45 241 7.9 22.4 19.5 24.5 25.7
Lipska et al., (India) 2007 15 – 45 214 12.6 7.5 25.2 11.2 43.5
Putaala et al., (Finland) 2009 15 – 49 1008 7.5 13.8 19.6 26.0 31.0
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TABLE 5. Potential New Risk Factors for Ischemic Stroke
Genetic factors/genotypes
    Angiotensin-converting enzyme genotype
    Factor V Leiden
    Prothrombin G20210A
    MTHFR
    Human platelet antigen type 1
    Factor XIII
    Apo E
    Plasminogen activator inhibitor-1 4G/5G genotypes
    Phosphodiesterase 4D
    5-Lipooxygenase–activating protein
Inflammatory markers
    Leucocyte count
    Monocyte count
    High-sensitivity C-reactive protein
    Soluble CD40 ligand
    Serum amyloid A
    Interleukins (IL-6, IL-18)
    Vascular and cellular adhesion molecules
    Myeloperoxidase
    Matrix metalloproteinase-9
Infectious agents
    Cytomegalovirus
    Herpes simplex virus
Chlamydia pneumonia
Helicobacter pylori
Legionella sp
    Periodontal disease
Lipid-related factors
    Small, dense LDL
    Lipoprotein (a)
    Remnant lipoproteins
    HDL subtypes
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 Lipoprotein-associated phospholipase A2
    Adiponectin
Oxidative stress
    Oxidized LDL
Biomarkers of hemostasis/thrombosis/impaired fibrinolysis
    Fibrinogen
    Protein Z
    Von Willebrand factor antigen
    Plasminogen activator inhibitor-1
    Tissue-type plasminogen activator
    Factors V, VII, and VIII
    D-dimer
    Fibrinopeptide A
    Prothrombin fragment 1 and 2
    Antiphospholipid antibodies
Platelet-related factors
    Platelet aggregation
    Platelet activity
    Platelet size and volume
Functional markers
   Endothelial dysfunction
   Arterial compliance, elasticity, stiffness (e.g., pulse
             pressure)
  Ankle-brachial systolic pressure index
  B-type natriuretic peptide
  Microalbuminuria
  Ctstatin C
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Studies are being done on the following markers
Biomarkers General Features Ischemic Stroke Studies
BNP Vasoactive peptide hormone  BNP in acute phase
Natriuretic, diuretic, and
vasodilator activity
 BNP predicts poststroke mortality
Cardiac and cerebral origin
DD Products of degradation of fibrin DD in acute, subacute, and
chronic phases
Marker of hemostatic imbalance  DD in cardioembolic stroke
Predictor of new vascular events
and prognostic role
S100b Calcium-binding protein  S100b in acute phase
Synthesized in astroglial cells S100b associated with clinical
deficit, infarct volume, and
functional disability
Marker of brain damage
RAGE Transmembrane receptor ? RAGE in acute, sub acute and
chronic phases
Immunoglobulin superfamily
Expressed by endothelial cells,
mononuclear cells, and neurons
Overexpressed at sites of
vascular damage
sRAGE have antiatherogenic
effects
CRP Pentraxin
Acute-phase protein; participates
in the systemic response to
inflammation
? CRP in acute phase
Predictor of risk of cerebrovascular
events
Prognostic value after stroke
Hepatic and extrahepatic
synthesis
MMP-9 Proteolytic enzyme  MMP-9 in acute phase
Involved in tissue remodeling  MMP-9 associated with
hemorrhagic transformation
Important role in
neuroinflammation
Correlated with infarct size and
clinical deficit
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Chimerin Nonprotein kinase C (GAP
family)
? chimerin in acute phases
Synthesized by neurons ( 1
isoform)
Regulatory function in actin
repolymerization
(neurocytoskeleton)
Secretagogin Calcium-binding protein  Secretagogin in acute phase
Expressed in neuroendocrine
cells
Marker of neuronal death
Neurotrophin
        -3
"Neuronal survival factor"
(neurotrophin family of growth
factors)
Endogenous neurotrophin-3
enhances neuronal injury
during acute stroke
 Neurotrophin-3 synthesis has
neuroprotective role
Caspase-3 Cysteine protease Activation of caspase-3 in
permanent and transient brain
ischemia
"Executioner" in apoptosis Caspase activation after
ischemia-induced brain
damage
? BNP : Brain Natriuretic Peptide
? DD : D-Dimer
? RAGE : Receptor for advanced Glycosalated end Products
? CRP : C-Reactive Protein
? MMP : Matrix Metallo Proteinase
Still experiment has to be done to reveal lot other significant biomarkers
for stroke.
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HOMOCYSTEINE
Cardiovascular morbidity and mortality is expected to rise exponentially
in developing countries due to the epidemiological transition43 that these
countries are going through currently.  It is this magnitude of the problem
which has forced the Indian   scientists to look for preventive aspects to curb
the increasing mortality through cardiovascular diseases. In this context,
Homocysteine plays a role in being easily reversible risk factors for
atherosclerosis.
Homocysteine Metabolism:
Homocysteine metabolism is greatly impacted by enzyme function,
lifestyle choices and nutritional status.
Gender and Genetics:
Women tend to have lower basal levels than men and neither
contraceptives nor Hormone replacement therapy seem to alter their levels
significantly.
Epidemiological evidence has shown homocysteine levels to be over
45% lower in westernized adult black Africans than in age-matched white
adults, revealing racial genetic differences in homocysteine metabolism.
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Lifestyle
A marked positive dose-response relation between coffee consumption
and plasma Homocysteine levels was observed. Cigarette smoking and chronic
ingestion of alcohol has also been associated with increased homocysteine
levels.
Nutritional considerations and metabolism
Those individuals in the lowest quartiles for serum folate and vitamin
B12 have significantly higher concentrations of homocysteine. Those having
lowest quartile of serum pyridoxal 543 phosphate(p5p – the bioactive form of
vitamin B6) also have increased homocysteine concentrations. The various
metabolic steps where these vitamins play a role is depicted in Fig.
1. The first step in the synthesis of homocysteine is the formation of
S-adenosyl methionine (Adenometh), an important methyl donor,
from methionine. Adeno-metho is then converted to SA denosyl
homocysteine  (Adeno-Hcy), which is further hydrolyzed to yield
homocysteine and adenosine depending on whether there is a
relative excess or a deficiency of  methionine, homocysteine may
then enter either transulphuration or remethylation pathways.
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HOMOCYSTEINE METABOLISM
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1. Remethylation
In the remethylation cycle, homocysteine is salvaged by the acquisition
of a methyl group in a reaction catalyzed by methionine synthase, NS-methyl-
tetrahydrofolate is the methyl donor in this reaction, and N5, N10 – Methylene
tetrahydrofolate reductase functions as a catalyst in the remethylation process.
2. Transulphuration
Under conditions in which an excess of methionine is present or
cysteine synthesis is required,homocysteine enters the transulphuration
pathway. In this way, homocysteine condenses with serine to form
cystathionine in a reaction catalyzed by the vitamin B6 – dependent enzyme
cystathionine B synthase. Cystathionine is subsequently hydrolysed to form
cysteine, which may then be incorporated into glutathione and further
metabolized to sulphate and excreted in the urine.
HYPERHOMOCYSTEINE REFERENCE RANGE
Sex Age Lower limit(micromol/litre)
Upper limit
(micromol/litre)
Female
12–65 years 3.0 12.0
>65 years 15.0 20.0
Male
12–65 years 6.0 15.0
>65 years 15.0 20.0
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Kang and co-workers have classified Hyperhomocysteinaemia as follows:
Mild : 15 – 30 micromole per litre
Moderate: 30 – 100 micromole per litre
Severe : > 100 micromole per litre
In some subjects, fasting levels may be in the normal range, but high
plasma Homocysteine level may be seen after a methionine loading test.
Plasma homocysteine levels may be altered by both inherited and acquired
factors (Table – 1).
Table – 1
Factors influencing homocysteine metabolism
Inherited Enzyme
Deficiencies in the metabolic pathway (cystathionine B
synthase, 5, 10 – Methylene tetrahydrofolate reductase,
methionine synthase)
Age and sex Advancing age, male sex, menopause
Nutritional
deficiencies
Folic acid, vitamin B6 and B12
Disease Status
Renal failure, malignancies, psoriasis, rheumatoid
arthritis, Systemic lupus eythematosus,
hypothyroidism, diabetes mellitus.
Medications
Metformin, methotrexate, anticonvulsants, niacin and
theophylline, decreased levels of betaine
33
Total homocysteine encompasses protein bound and unbound fractions,
with 80% being in the bound state. The term homocysteine referes to combined
pool of homocysteine, a mixed disulphide. Homosysteine and risk of
cardiovascular disease cross – sectional studies have consistently demonstrated
an association between blood levels of homocysteine and the anatomic extent
of atherosclerotic vascular disease in the coronary, cerebral and peripheral
circulation. In 1995, Boushey52 et.al. performed a meta analysis of 27
observational studies involving about 4000 patients.  An elevated blood level of
homocysteine was associated with an increased risk of vascular events in the
coronary (odds Ratio – OR : 1.7),cerebral (Or : 2.5) and peripheral (OR :6.8)
circulations. It was estimated that around 10% of coronary heart disease deaths
in middle aged men might be prevented by a 5 micromol/L reduction in blood
levels of homocysteine. Thus proving the fact that the magnitude of risk was
similar to that for elevated cholesterol.Knekt53 et.al. studied total homocysteine
level for its prediction of major coronary artery disease events among women.
A total of 74 and 75 major coronary events which occurred in women with and
without known heart disease, respectively, during a 13 year follow-up were
studied.  Amongst women with baseline heart disease, the relative risk of such
events, adjusted for age, smoking, hypertension, diabetes, serum cholesterol
and body mass index was 3.32 in the highest homocysteine quartile compated
with the lowest quartile. Amongst women free of heart disease of baseline, the
corresponding relative risk was 0.77.
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Mechanism of Homocysteine Induced Vascular Damage
Pathogenesis of vascular disease54
There are numerous studies which have explored sites of adverse
influence of homocysteine,including the endothelial surface, vascular smooth
muscle cells,connective tissue, interactions with plasma lipoproteins, clotting
factors and platelets. The endothelium has received considerable attention as
the final common pathway of homocysteine  induced vascular injury.
Nitric – oxide Thrombomodulin
Homocysteine
Protects Endothelium
Endothelium
Damage Endothelium
Depletion of NO and TM
Reactive Oxygen Species
Oxidation
35
Endothelium in health regulates vascular tone by modulating endothelium –
derived relaxing factor (nitric oxide : NO). It also modulates the coagulation
cascade through protein C and antithrombin III interactions. By influencing
tissue plasminogen activator it also has fibrinolytic functions. It also controls
the composition of the subendothelial matrix and smooth muscle cell
proliferation. Many of these normal properties may become deranged in the
presence of elevated homocysteine levels.
Plasma homocysteine and coronary artery disease risk in Indians
Though the casual role of homocystiene in the genesis of atherosclerosis
is getting established in the recent past yet there are conflicting statements
made about its role and implications in the disease process. The researchers in
their study have demonstrated that though the levels of homocysteine have
been found to be elevated in various atherosclerosic events yet there is no solid
evidence to correlate the two. The finnish population study56, the multiple risk
factor intervention trial (MRFIT)57 and the atherosclerosis in communities
(ARIC)58 study did not show any relation of plasma homocysteine levels to
cardiovascular disease. One provocative view holds that
hyperhomocysteinaemia, instead of being an antecedent of cardiovascular
events, may be a markers of tissue damage or repair following them59.
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Contrast to above statement there are several other recent studies who
have investigated and confirmed the contribution of homocysteine to
cardiovascular disease (CVD) risk both among immigrant Indians60 and those
living in India61. Chambers et al conducted two parallel case control studies,
one in Europeans and the other in Indians, to evaluate fasting and
postmethionine load homocysteine as risk factor for cardiovascular disease.
They found that elevated plasma homocysteine levels were independently
associated with cardiovascular disease in both UK Indians and Europeans.
They showed that the odd ratio for coronary heart disease for a 5 mmol/L
increment in plasma homocysteine was 1.3 in Europeans and Indians.
However, the Indians in this study were not evaluated for the other known
associations of cardiovascular disease characteristic of Indian ethnicity, namely
abnormal waist-hip ratio (WHR), raised Lipoprotein (a) and hyperinsulinemia.
The strength of this association, after correction for these potentially
confounding risk variables, would have provided better insight into the place of
homocysteine in the risk factor spectrum. In a population study from Canada
involving nearly a thousand participants from three ethnic groups (South
Asians, Europeans and Chinese), the presence of clinical cardiovascular disease
and carotid intimal medial thickness measured by B-mode ultrasound were
correlated with conventional and non-conventional risk factors62. Even the
South Asians had significantly higher levels of plasma homocysteine than their
European and Chinese counterparts, this did not translate into an independent
association of homocysteine with cardiovascular disease.
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In a population  based Study of South Asians in Canada63   and a case-
control Study of Asians living in the UK64 have shown that Indians tend to
have higher homocysteine levels as compared to European and Chinese
population. This could be attributed to the reduced intake of vitamin B12 in
Indians and the prolonged cooking of vegetables which has been observed in
some Indian households in the UK.
Though there is lot of emphasis given to the casual relationship of
hyperhomocystenimia to cardiovascular disease the other components of
vascular involvement should not be ignored as they also contribute for
significant morbidity and mortality.
Homocysteine: A new emerging risk factor for hypertension
Vascular endothelium does play a critical role in the control of blood
pressure. There is a very optimal balance between the vasocontrictive and
vasodilator factors acting on the vessel wall and thus contributing for its tone.
Mendis et al65 in their study conducted in Sri Lanka demonstrated the
association between hypertension and homocysteine levels. Serum
homocysteine were measured in 86 patients with a diagnosis of essential
hypertension and compared with those of an age and sex matched group. They
found that patients with hypertension had significantly higher mean serum
concentrations of homocysteine. Bortolotto LA et al66 demonstrated that
hypertensive patients with high levels of homocysteine are associated with
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increased arterial stiffness (measured by aortic distensibility and homocysteine
levels can help in cardiovascular risk assessment in hypertensive population.
Adunsky et al67 studied the distribution of total homocysteine levels in a
sample of older patients consecutively admitted following acute ischemic
cerebral stroke, as compared with healthy controls. 137 stoke patients and 132
healthy controls (Age 0.06 = 60 years) participated in this study. The results
showed that stroke patients (mean age 74 years) had higher homocysteine
levels as compared with controls (13.8 and 9.8) respectively.
Peripheral vascular disease
Elevated homocysteine levels have been established as an independent
risk factor for intermittent claudication and deep vein thrombosis. A four-fold
increase in risk of peripheral vascular disease was noted in individuals with
hyperhomocysteine levels68. An increased risk of peripheral vascular occlusion
has been noted in women taking oral contraceptives, which might be lined to
the significantly increased homocysteine levels in women so affected69.
In one survey conducted by NIMHANS, doctors found that 40 per cent
of stroke patients under 40 had high levels of homocysteine compared to only
17 per cent normal people found to have high levels of this amino acid.
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Homocysteine levels in Vegetarians and Non-vegetarians:
Studies72,73 have shown elevated homocysteine in people who are on
strict vegetarian diet since childhood.  Reason attributed are decrease amount
of Vit.B12 in their diet.  But the difference between homocysteine in
vegetarians and non-vegetarians are not gross.  Because, vegetarians may get
Vit.B12 from milk or from bacterial contaminants in vegetables and fresh fruits
as they carry significant amount of Vit.B12.  Other food substances71 which
have some Vit.B12 are soya beans, legumes, cottage cheek.
Various studies have shown values of homocysteine in non-vegetarians
is between 10 – 13 micromol/L70,72,73 and in vegetarians is between 12 – 15
micromol/L70,72,73.  Some studies have shown increased incidence of acute
vascular events (especially stroke) in vegetarians when compared to non-
vegetarians71.  Still lot of evidence is required to prove this issue.
At least 14 studies have measured the homocysteine levels in
vegetarians. The following diagram shows the blood B12 levels of the
participants of 13 of those studies (one did not report B12 levels70).
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Serum B12 Levels in Homocysteine Studies on Vegetarians (pg/ml)
A - Most of these vegetarians did not supplement their diets with B12.
USA '985, USA '99 (averaged 5.6 µg B12/day)6, Australia '997, Chile '998, Chile '009, Slovak Republic
'0010, India '0111, Germany '0112, Taiwan '0213, Italy '0214, Germany '0215, Taiwan '0317, Germany
'0318, Germany '03 (took "B vitamins", amounts not reported)18
Normal B12 levels are from 200 to 900 pg/ml.  The above diagram
shows that vegans had the lowest B12 levels, followed by lacto-ovo-
vegetarians, and then non-vegetarians.
MATERIALS AND METHODS
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MATERIALS AND METHODS
Study Population:
Total of 50 patients with stroke in young were enrolled for the study.
Patients were selected from medicine wards of the Institute of Internal
Medicine.
Patients are selected for the study who satisfied all the inclusion and
exclusion criteria. Written consent was obtained from all the patients/care
providers.
Study Duration:
This study was conducted for a period of eighteen months from January
2009 to June 2010.
Study Design:
Cross – Sectional Study.
Methods:
Detailed clinical history was taken from each patients and a complete
review of their case notes performed. A complete clinical examination of the
nervous system and cardiovascular system was done for each patient.
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Laboratory Study
To all selected cases, following investigations were taken:
1. Complete Blood Count.
2. Renal Function Test
3. Liver Function Test
4. Prothrombin Time / INR
5. Activated Partial Thromboplastin Time
6. ECG
7. Echocardiography
8. CT Brain
9. Fasting Blood Sugar
10. Fasting Lipid Profile
11. Thyroid Function Test
12. Carotid & Vertebral Doppler (4 Vessel Doppler)
13. ELISA (HIV)
14. VDRL (Syphilis)
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15. Rheumatoid Factor
16. Anti-nuclear Antibodies
17. Pregnancy Test
18. Fasting Plasma Homocysteine
(Using photometric analysis)
19. Other relevant investigations.
Inclusion Criteria
1. Age > 12, < 40
2. Ischemic Stroke
Exclusion Criteria
1. Age <12, > 40
2. Hemorraghic Stroke
3. Smoking
4. Alcoholism
5. Known Systemic Hypertension
6. Diabetes Mellitus
7. Cardiac Disease
8. Peripheral Vascular Disease
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9.  Renal Disease
10. Hypothyroidism
11. Drugs which interfere with Homocystine  Metabolism (Anti-
      Epileptics, Anti-Chemotherapeutic Drugs, Methformin Theophylline
      Niacin and others)
12.  Dyslipidemia
13 . Other Inflammatory States, Systemic Lupus Erythematosus
      Rheumatoid Arthritis, Psoriasis
14. Patient with previous history of stroke
Statistical Analysis
The significance value is found using standard error of mean and student
T test. The final results were obtained using SPSS software. Variables were
considered to be significant if (P < 0.05)
OBSERVATION AND RESULTS
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OBSERVATIONS
S.No. Baseline Features Total Number
01. Male 42
02. Female 08
03. Non-vegetarians 41
04. Vegetarians 05
05. Family History 05
06. Death 03 (2 Males, 1
Female)
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AGE WISE DISTRIBUTION OF STROKE
Age group No. of patients Percentage
<20 03 06%
21 - 30 20 40%
31- 40 27 54%
3 patients (6%) are below age 20
20 patients (40%)  are between age 21 to 30
27 patients (54%) are between age 31 – 40
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SEX WISE DISTRIBUTION OF STROKE
MALE FEMALE
NO. OF PATIENTS 42 8
Percentage 84% 16%
42 Patients (84%) are males
8 patients (16%) are females
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DIET BASED DISTRIBUTION
41 Patients (82%) are Non-vegetarians
9 patients (18%) are Vegetarians
DIET PATTERN NUMBER OF
PATIENTS
PERCENTAGE
NON-VEGETARIANS 41 82%
VEGETARIANS 9 18%
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HYPERHOMOCYSTINEMIA DISTRIBUTION
PATIENT WISE
HOMOCYSTEINE
LEVELS (micro mol/L)
NUMBER OF
PATIENTS
PERCENTAGE
MILD
(15-30)
4 22.22%
MODERATE
(31-100)
14 77.77%
SEVERE
(>100)
0 0%
4 Patients (22.22%) are having mild hyperhomocystinemia.
14 Patients (77.77%) are having moderate
hyperhomocystinemia.
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HYPERHOMOCYSTINEMIA DISTRIBUTION
AGE WISE
AGE
GROUP
NO. OF PATIENTS WITH
HYPERHOMOCYSTENIMIA PERCENTAGE
<20 1 33.33%
21-30 4 20.0%
31-40 13 48.12%
     1 Patient with hyperhomocystinemia is below age 20.
     4 Patients with hyperhomocystinemia are between 21 – 30.
     13 Patients with hyperhomocystinemia are between 31 – 40.
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HYPERHOMOCYSTINEMIA DISTRIBUTION
SEX WISE
SEX NUMBER OF PATIENTS WITHHYPERHOMOCYSTENIMIA PERCENTAGE
MALES 14 33.33%
FEMALES 4 50%
14 Out of 42 males had hyperhomocystinemia
4 out of 8 females had hyperhomocystinemia
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HYPERHOMOCYSTINEMIA DIET BASED DISTRIBUTION
DIET
PATTERN
TOTAL
NO. OF
PATIENTS
NO. OF PATIENTS WITH
HYPERHOMOCYSTENIMIA
PERCENTAGE
NON-
VEGETARIANS
41 14 34.15%
VEGETARIANS 9 4 44.44%
14 out of 41(34.15%) non-vegetarians had hyperhomocystenimia
4 out of 9 (44.44%) vegetarians had hyperhomocystenimia
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HYPERHOMOCYSTENIMIA SEVERITY DISTRIBUTION
SEXWISE
SEX HYPERHOMOCYSTENIMIA
SEVERITY
NO. OF PATIENTS WITH
HYPERHOMOCYSTENIMIA
MALES
MILD 4
MODERATE 10
SEVERE 0
FEMALES
MILD 0
MODERATE 4
SEVERE 0
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DIET BASED HYPERHOMOCYSTENIMIA SEVERITY
DIET PATTERN HYPERHOMOCYSTENIMIA
SEVERITY
NUMBER OF PATIENTS
WITH HYPERHOMO-
CYSTENIMIA
NON-
VEGETARIANS
MILD 3
MODERATE 11
SEVERE 0
VEGETARIANS
MILD 1
MODERATE 3
SEVERE 0
Among non-vegetarians, 3 patients had mild
hyperhomocystenimia; 11 patients had moderate
hyperhomocystenimia and none had severe
hyperhomocystenimia.
Among vegetarians, 1 patient had mild hyperhomocystenimia;
3 patients had moderate hyperhomocystenimia and none had
severe hyperhomocystenimia.
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SEX NUMBER OF DEATH
MALES 2
FEMALES 1
57
T-Test
MALES
One-Sample Statistics
N Mean
Std.
Deviation Std. Error
Mean
Homocysteine 42 22.4826 23.47244 3.62188
One-Sample Test
Test Value = 15
t df
Sig.
(2-tailed)
Mean
Difference
95% Confidence
Interval of the
Difference
p value Lower Upper
Homocysteine 2.066 41 .045 7.4826 .1681 14.7971
‘p’ value is 0.045 which is less than 0.05.  Hence, this p value is statistically
significant.
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T-Test
FEMALES
One-Sample Statistics
N Mean
Std.
Deviation
Std. Error
Mean
Homocysteine 8 30.2838 21.58607 7.63183
One-Sample Test
Test Value = 12
t df
Sig. (2-
tailed)
Mean
Difference
95% Confidence
Interval of the
Difference
 p value Lower Upper
Homocysteine 2.396 7 .048 18.2838 .2373 36.3302
‘p’ value is 0.048 which is less than 0.05.  Hence, this p value is statistically
significant.
DISCUSSION
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DISCUSSION
In our study, we took 50 patients with first attack of acute ischemic
stroke between age group 12 and 40.  We have excluded common conventional
risk factors for stroke in young.  These patients are put on all important
investigations including fasting plasma homocysteine levels.
We had 42 male patients and 8 female patients with stroke.  Out of
them, 41 were taking non-vegetarian food substance and 9 were taking strict
vegetarian food substance since their childhood period.  These patients are
carefully chosen as to exclude some common conditions and substances which
causes significant elevation of homocysteine level.  Cross sectional study was
done on these patients by obtaining fasting plasma homocysteine on the second
day after admission.  The results are obtained after photometric analysis.
Our study shows prevalence of stroke in young is more in males when
compared to females (42 patients versus 8 patients).  Also the prevalence of
hyperhomocystenimia is more common in males (14 patients out of 42
patients) versus females (4 patients out of 8 patients).  But the proportion of
hyperhomocystenimia is more in females than males (50% versus 33.33%).
Our study shows occurrence rate of stroke increases as the age increases.
It is rare before age 20 (only 3 patients below age 20 had stroke).  Also the
prevalence of hyperhomocystenimia is more in age group between 31 – 40
(48%) as 13 out of 27 had hyperhomocystenimia.
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Our study showed 14 out of 41 non-vegetarians had
hyperhomocystenimia (34.15%) also 4 out of 9 vegetarians had
hyperhomocystenimia (44.44%).  This shows that vegetarians have higher
prevalence of hyperhomocystenimia than non-vegetarians.
Our study shows most of the patients are in moderate range of
hyperhomocystenimia (14 out of 18) i.e. 77.77% and none of the patients had
severe hyperhomocystenimia.  Five patients in our study had family history of
stroke out of which 3 had hyperhomocystenimia (2 males and 1 female).
In our study, 3 out of 50 patients died in the course of treatment in the
hospital during the study period.  All these patients (2 males and 1 female) had
hyperhomocystenimia (in moderate range).
‘P’ values were calculated by setting a separate cut-off values for
females and males.  ‘P’ values calculated from our study showed to be in the
significant range (i.e. <0.05).
 From this study, it is clearly shown that homocysteine has a definite
role in stroke in young, also proportion of hyperhomocystenimia is more
among vegetarians  than the non-vegetarians.
CONCLUSION
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CONCLUSION
1. High prevalence of elevated homocysteine in patients with
stroke in young.
2. There is a definite associated of homocysteine in patients with
stroke in young.
3. Homocysteine may play a role in pathogenesis as mentioned in
the literature above which needs further studies.
4. Level of homocysteine has a definite role in determining the
mortality in patients with stroke in young.
5. Level of homocysteine has its implication in prognosis and
outcome.
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SCOPE FOR FUTURE RESEARCH
Hyperhomocystenimia seems to be a risk factor for thrombotic events
via its effects on platelets, vascular endothelium, and coagulation proteins.
Atherogenic mechanisms promoted by homocysteine include altered Factor V
formation, which catalyzes prothrombin to thrombin, decreased protein C
activation, diminished fibrinolysis, and platelet aggregation. A closer look is
needed at the
interaction between homocysteine and clotting factors, fibrinolytic parameters,
and endothelial-derived factors.
Prospective trials utilizing treatments for lowering fibrinogen and
homocysteine (e.g. fibrates and folate/B-vitamins) are needed to evaluate the
merit of clinical evaluation of these variables. A reduction in risk of stroke
accompanying the reduction of these concentrations must also be demonstrated
before clinical determination of these values is put into practice. Several drugs
have been identified which lower fibrinogen concentrations, however these
drugs have additional pharmacological effects making it difficult to attribute
any benefits on improving stroke risk to reduction of fibrinogen. Agents for the
selective lowering of fibrinogen concentrations are under development.
Treatment of homocysteinemia and its vascular complications includes folate,
vitamins B12 and B6, betaine, and anticoagulants.
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Higher levels of these cofactors are associated with lower concentrations
of homocysteine. No information is available as to whether a reduction in
homocysteine concentrations by increased intake of supplements or foods high
in these vitamins reduces stroke risk.
Studies has to be done to know the exact correlation between food
pattern and homocysteine levels and the role of these foods in acute vascular
events.
The scientists involved in studying homocysteine are already clear
danger-signal, as they have been ignored for many years while the focus was
on cholesterol, and will now fight hard to maintain and improve their new
status. They are already starting to make wildly exaggerated claims, such as
"studies now underway will prove that controlling homocysteine is the best
way to deal with vascular disease." As well as vascular disease, homocysteine
is now being 'linked' with virtually every other known ailment, Alzheimer’s,
Bechets disease ,inflammatory bowel disease certain vasculitis ,osteoporosis
and strokes. All that seems certain at the moment is that elevated homocysteine
is associated with ageing, as are most of the diseases 'linked' to homocysteine.
Homocysteine is being labelled as “NEWER CHOLESTEROL” by
certain epidemiologist.Still more study is required to know the exact relation of
homocysteine in various diseases.
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ANNEXURE
? PROFORMA
? MASTER CHART
? ABBREVIATIONS
? ETHICAL   COMMITTEE   APPROVAL
ORDER
PROFORMA
Name Sex Age
Religion Address
Citizenship
Complaints:
Past H/o:
Similar episodes Bronchial Asthma
Transient Ischemic Attack Tuberculosis
Diabetes Mellitus Human immunodeficiency virus
Hypertension Drug Allergy
Coronary Artery Disease Others
Personal H/o:
Diet (Vegetarian/Non.Vegetarian)
Marital status Premarital / Extra marital sexual history
Mensural H/o
Habits: Alcohol Tobacco chewing
Smoking Betel Nut chewing
Family H/o:
Treatment H/o:
GENERAL EXAMINATION:
VITALS Peripheral Pulses
HEAD TO FOOT EXAMINATION
SYSTEMIC EXAMINATION
CVS
RS
Abdomen
Central Nervous system Examination
PROVISIONAL DIAGNOSIS
Sl
.N
o
N
am
e
A
ge Se
x
D
ie
t p
at
te
rn
Fa
m
ily
  H
/O
B
lo
od
 P
re
ss
ur
e
Fa
st
in
g 
B
lo
od
 S
ug
ar
<1
20
m
g%
T
ot
al
 C
ar
bo
hy
dr
at
e
<2
00
 m
g%
T
ri
gl
yc
er
id
e 
<1
50
 m
g%
L
ow
 D
en
si
ty
 L
ip
op
ro
te
in
<1
00
 m
g%
H
ig
h 
D
en
si
ty
 L
ip
op
ro
te
in
<5
0 
m
g%
 –
 F
em
al
e
<4
0 
m
g%
  -
 M
al
e
T
hy
ro
id
 S
tim
ul
at
in
g
H
or
m
on
e 
in
 n
or
m
al
 li
m
its
E
ch
oc
ar
di
og
ra
ph
y
C
T
 B
ra
in
4 
ve
ss
el
 D
op
pl
er
H
om
oc
ys
te
in
e 
L
ev
el
s
in
 M
ic
ro
m
ol
e/
L
M
al
e 
5 
– 
15
; f
em
al
e 
3 
– 
12
1 PRASANTH 33 M Non-Vegetarian No 160/90 Yes No No No No Yes No R  /MCA Nil 29.31
2 SARAVANAN 28 M Non-Vegetarian No 150/90 Yes No No No No Yes No L/PCA Nil 36.48
3 SELVAM 30 M  Non-Vegetarian No 120/80 Yes No No No No Yes No L /MCA Nil 10.52
4 JOHN 37 M Non-Vegetarian No 130/80 Yes No No No No Yes No R  /MCA Nil 9.22
5 MANI 28 M Non-Vegetarian No 134/80 Yes No No No No Yes No R  /MCA Nil 24.32
6 ELANGOVAN 38 M Non-Vegetarian No 150/90 Yes No No No No Yes MVP L/PCA Nil 5.48
7 DEVI 25 F Non-Vegetarian No 130/80 Yes No No No No Yes No L  /MCA Nil 52.42
8 ARUNAGIRI 35 M Vegetarian No 160/80 Yes No No No No Yes No R  /MCA Nil 20.66
9 AMUDHA 27 F Non-Vegetarian Yes 140/80 Yes No No No No Yes No R/ACA Nil 10.94
10 HABEEB 36 M Non-Vegetarian No 140/84 Yes No No No No Yes No L/PCA Nil 68.28
11 RANGASWAMY 39 M Vegetarian No No Yes No No No No Yes No R  /MCA Nil 12.38
12 CHRISTOPHER 34 M Non-Vegetarian No 150/80 Yes No No No No Yes No L  /MCA Nil 80.28
13 THULASI 28 F Non-Vegetarian No 140/90 Yes No No No No Yes PFO R  /MCA Nil 9.45
14 MARIMUTHU 38 M Non-Vegetarian No 140/86 Yes No No No No Yes No R  /MCA RCS 30.68
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15 RANI 22 F Vegetarian No 130/90 Yes No No No No Yes No R/PCA Nil 10.24
16 NAVEEN 27 M Non-Vegetarian No 140/90 Yes No No No No Yes No R/ACA Nil 12.38
17 VENKATESH 30 M Vegetarian No 150/84 Yes No No No No Yes No L  /MCA Nil 6.68
18 RAJALAXMI 29 F Non-Vegetarian No 130/90 Yes No No No No Yes No L  /MCA Nil 10.48
19 ABDULLA 37 M Non-Vegetarian Yes 130/80 Yes No No No No Yes No R  /MCA Nil 10.58
20 MURUGAN 18 M Non-Vegetarian No 150/90 Yes No No No No Yes No R  /MCA Nil 8.28
21 GUGAN 27 M Non-Vegetarian No 130/80 Yes No No No No Yes No R   /PCA Nil 7.56
22 BALAJI 35 M Non-Vegetarian No 140/80 Yes No No No No Yes No R  /MCA Nil 8.92
23 SIVA 33 M Non-Vegetarian No 126/80 Yes No No No No Yes No L /MCA Nil 10.37
24 ASLAM 24 M Non-Vegetarian Yes 179/100 Yes No No No No Yes MVP L/PCA Nil 68.48
25 ARUMUGAM 35 M Vegetarian No 150/90 Yes No No No No Yes No R/MCA Nil 7.76
26 RAMESH 26 M Non-Vegetarian No 120/80 Yes No No No No Yes No R/PCA Nil 8.82
27 PETER 36 M Non-Vegetarian No 130/80 Yes No No No No Yes No L/MCA Nil 20.38
28 ARUN 39 M Non-Vegetarian No 160/90 Yes No No No No Yes No L/PCA Nil 90.62
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29 SUSHEELA 38 F Non-Vegetarian No 150/90 Yes No No No No Yes No L/MCA Nil 45.26
30 SHANKAR 18 M Non-Vegetarian No 140/90 Yes No No No No Yes Pfo R/MCA Nil 10.56
31 VELU 32 M Non-Vegetarian No 150/90 Yes No No No No Yes No R/MCA RCS 40.68
32 RAMADOSS 27 M Vegetarian No 150/80 Yes No No No No Yes No L/MCA Nil 12.38
33 POOGODI 32 F Non-Vegetarian Yes 140/90 Yes No No No No Yes MVPS R/MCA Nil 55.24
34 RAHUMAN 38 M Non-Vegetarian No 150/90 Yes No No No No Yes No R/MCA Nil 12.38
35 DHARMAN 39 M Non-Vegetarian No 140/90 Yes No No No No Yes No L/MCA Nil 8.22
36 KUMARAN 26 M Non-Vegetarian No 160/80 Yes No No No No Yes No R/MCA Nil 7.36
37 RAJARAJAN 36 M Vegetarian No 150/90 Yes No No No No Yes No R/ACA Nil 40.72
38 ALAGAPAN 34 M Non-Vegetarian No 140/90 Yes No No No No Yes No L/MCA Nil 12.38
39 RAJENDRAN 36 M Non-Vegetarian No 150/90 Yes No No No No Yes No R/MCA Nil 11.38
40 SENTHILKUMAR 28 M Non-Vegetarian No 150/90 Yes No No No No Yes No L/MCA Nil 10.38
41 MANOHARAN 36 M Non-Vegetarian No 150/90 Yes No No No No Yes No R/MCA Nil 30.58
42 VEERASWAMY 28 M Non-Vegetarian No 140/86 Yes No No No No Yes No L/MCA Nil 7.72
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43 MOHAMAD RAFIK 38 M Non-vegetarian No 150/86 Yes No No No No Yes No L/MCA Nil 11.28
44 PUNITHA 18 F Vegetarian No 160/90 Yes No No No No Yes No R/MCA Nil 48.24
45 YOGESHWARAN 26 M Non-Vegetarian Yes 150/90 Yes No No No No Yes No L/MCA Nil 12.28
46 VISHNU 32 M Non-Vegetarian No 160/90 Yes No No No No Yes No R/MCA Nil 8.23
47 SHANKAR 35 M Non-Vegetarian No 120/80 Yes No No No No Yes No R/MCA Nil 9.62
48 DHINAKARAN 35 M Vegetarian Yes 160/90 Yes No No No No Yes No R/PCA Nil 90.78
49 JOSEPH 28 M Non-Vegetarian No 150/88 Yes No No No No Yes No R/MCA Nil 8.28
50 ESHWARAN 26 M Non-Vegetarian No 120/80 Yes No No No No Yes No L/PCA Nil 10.36
ABBREVIATIONS
CVA : CEREBRO VASCULAR ACCIDENT
CVD : CARDIO VASCULAR DISEASE
Hcy : HOMOCYSTEINE
R : RIGHT
L : LEFT
MCA : MIDDLE CEREBRAL ARTERY
ACA : ANTERIOR CEREBRAL ARTERY
PCA : POSTERIOR CEREBRAL ARTERY
RCS : RIGHT CAROTID (INTERNAL) STENOSIS
LCS : LEFT CAROTID (INTERNAL) STENOSIS
MVP : MITRAL VALVE PROLAPSE
PFO : PATENT FORAMEN OVULE
SLE : SYSTEMIC LUPUS ERYTHAMATOSIS
RA : RHEUMATOID ARTHRITIS

